An Updated View of the Trypanosoma cruzi Life Cycle: Intervention Points for an Effective Treatment
Metadata
Show full item recordAuthor
Martín Escolano, Javier; Marín Sánchez, Clotilde; Rosales Lombardo, María José; Medina Carmona, EncarnaciónEditorial
American Chemical Society
Materia
Chagas disease Drug discovery Evolution model Genetic diversity Life cycle Morphological forms Target product profile Tropism Trypanosoma cruzi
Date
2022-06-02Referencia bibliográfica
ACS Infect. Dis. 2022, 8, 6, 1107–1115. [https://doi.org/10.1021/acsinfecdis.2c00123]
Sponsorship
Junta de Andalucia E-BIO-464-UGR20; Junta de Andalucia (Proyectos I+D+I FEDER Andalucia 2014-2020); Alfonso Martin Escudero FoundationAbstract
Chagas disease (CD) is a parasitic, systemic, chronic, and often
fatal illness caused by infection with the protozoan Trypanosoma cruzi. The
World Health Organization classifies CD as the most prevalent of povertypromoting
neglected tropical diseases, the most important parasitic one, and the
third most infectious disease in Latin America. Currently, CD is a global public
health issue that affects 6−8 million people. However, the current approved
treatments are limited to two nitroheterocyclic drugs developed more than 50
years ago. Many efforts have been made in recent decades to find new therapies,
but our limited understanding of the infection process, pathology development,
and long-term nature of this disease has made it impossible to develop new
drugs, effective treatment, or vaccines. This Review aims to provide a
comprehensive update on our understanding of the current life cycle, new
morphological forms, and genetic diversity of T. cruzi, as well as identify
intervention points in the life cycle where new drugs and treatments could achieve a parasitic cure.